Skip to content
value.today
Clene Inc. logo

Clene Inc.

CLNN
$49 Mmarket cap on Oct 14, 2026+31.9% since Jan 2024
Compare
World rank
#21,385
Revenue
$0 M
For year ending December-2025
Net income
$-26 M
-13085.0% margin
SEC filing
Employees
—

Clene Inc. in brief

Clene Inc. is a listed company in the Biotechnology industry, based in Salt Lake City, Utah, USA. Its market value was $49 M on 14 October 2026, which makes it the 21,385th largest listed company in the world and the 3,868th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $26 M. Robert Dee Etherington is its chief executive. Its largest product and service lines by sales in 2025 were Royalty (40%). Its shares trade under the symbol CLNN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Clene Inc.

Clene Inc. is a Clinical Stage Biopharmaceutical company focused the treatment of neurodegenerative diseases company. The company annual revenue is 68.2 million USD as on 2020. The headquarters is in USA.

Clene Inc. timeline

3 events, 2020–2021
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed Clene Inc.
    Formerly Chelsea Worldwide Inc..
  4. 2021
  5. 💰
    Record revenue of $1 million
    FY2021, the highest of the 6 years on record.

Events of Clene Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$67 M$134 M$201 M$268 M2023202420252026

World rank over time

▼ down 3,771 places since 2022
2022-01-07: #17689#17,68920222022-12-25: #23153#23,15320222023-07-30: #22042#22,04220232024-01-05: #26305#26,30520242026-03-08: #10758#10,75820262026-08-01: #19291#19,29120262026-10-14: #21460#21,4602026

Rank in USA: #3,652 (Jan 2022) · #4,505 (Dec 2022) · #4,282 (Jul 2023) · #4,192 (Jan 2024) · #2,104 (Mar 2026) · #3,718 (Aug 2026) · #3,851 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
203.4×
Price / book
—
Free cash flow yield
-38.1%
Net margin (TTM)
-11170.8%
Operating margin
-11540.0%
Return on equity
—
Liabilities / assets
197.0%
Net debt
$13M
Revenue growth
-41.2%
R&D / revenue
7005.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-16M—FY19Fiscal year ending Dec 2020: revenue $0M, net income $-19M$0MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-10M$1MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-30M$0MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-50M$1MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-39M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-26M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M-41.2%$-23M$-26M-13085.0%
Dec 2024$0M-47.7%$-33M$-39M-11588.2%
Dec 2023$1M+38.3%$-41M$-50M-7615.4%
Dec 2022$0M-34.7%$-48M$-30M-6366.0%
Dec 2021$1M+242.9%$-50M$-10M-1352.8%
Dec 2020$0M—$-20M$-19M-9181.0%
Dec 2019——$-16M$-16M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-19M$0M$-19M——
Dec 2024$-21M$0M$-21M——
Dec 2023$-30M$0M$-31M——
Dec 2022$-39M$5M$-44M——
Dec 2021$-35M$1M$-36M$-0.16—
Dec 2020$-19M$0M$-19M$-1.10—
Dec 2019$-13M$0M$-13M$-0.93—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$0M
Net income, trailing 12 months
$-27M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-14M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-1M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-7M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-9M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-9M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-8M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-13M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $4M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+200.0% on a year earlier), net income $4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Clene Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-23 M
Net income
$-26 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$18 M
Total liabilities
$36 M
Total equity
$-18 M

As of December-2025

Top 38 institutional investors in Clene Inc.#

As of Sep 30, 2026
38 institutions held 2.7 M shares (about 18.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 16.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Clene Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Scoggin Management LP500,000-100,000 (-16.67%)3.47%$2 MNov 16, 2026
2Boxer Capital Management, LLC477,5150 (0.00%)3.32%$2 MNov 16, 2026
3Vanguard Capital Management LLC333,406-300 (-0.09%)2.32%$1 MNov 13, 2026
4Ensign Peak Advisors, Inc321,461-26,601 (-7.64%)2.23%$1 MNov 12, 2026
5Empery Asset Management, LP221,660-694,872 (-75.82%)1.54%$1 MNov 16, 2026
6Cantor Fitzgerald, L. P.140,000New0.97%$1 MNov 16, 2026
7Citadel Advisors LLC114,847New0.80%$0 MNov 16, 2026
8Geode Capital Management, LLC112,569+10,354 (+10.13%)0.78%$0 MNov 6, 2026
9Shay Capital LLC75,809New0.53%$0 MNov 16, 2026
10Vanguard Fiduciary Trust Co73,009+15,244 (+26.39%)0.51%$0 MNov 13, 2026
11BlackRock, Inc.67,551+5,992 (+9.73%)0.47%$0 MNov 13, 2026
12State Street Corp37,901+8,100 (+27.18%)0.26%$0 MNov 12, 2026
13Parsons Capital Management Inc/ri37,2430 (0.00%)0.26%$0 MOct 28, 2026
14Peak6 LLC30,0120 (0.00%)0.21%$0 MNov 13, 2026
15Jane Street Group, LLC25,939+15,736 (+154.23%)0.18%$0 MNov 12, 2026
16Lunt Capital Management, Inc.21,287-30,973 (-59.27%)0.15%$0 MOct 30, 2026
17Morgan Stanley19,792-66 (-0.33%)0.14%$0 MNov 13, 2026
18Northern Trust Corp19,7230 (0.00%)0.14%$0 MNov 16, 2026
19ADAR1 Capital Management, LLC15,0000 (0.00%)0.10%$0 MNov 16, 2026
20XTX Topco Ltd12,724New0.09%$0 MNov 16, 2026
21Squarepoint Ops LLC11,920New0.08%$0 MNov 9, 2026
22Arax Advisory Partners11,1400 (0.00%)0.08%$0 MNov 12, 2026
23Penn Davis Mcfarland Inc11,0000 (0.00%)0.08%$0 MOct 23, 2026
24Two Sigma Investments, LP10,115New0.07%$0 MNov 16, 2026
25Wells Fargo & Company/mn5,9270 (0.00%)0.04%$0 MNov 16, 2026
Show all 38: investors 26 to 38
Institutional investors 26 to 38 in Clene Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Global Advisers, LLC5,6090 (0.00%)0.04%$0 MNov 13, 2026
27UBS Group AG3,228+2,877 (+819.66%)0.02%$0 MNov 10, 2026
28PNC Financial Services Group, Inc.2,7350 (0.00%)0.02%$0 MNov 6, 2026
29Atlantic Private Wealth, LLC2,2050 (0.00%)0.02%$0 MNov 9, 2026
30Steward Partners Investment Advisory, LLC2,0000 (0.00%)0.01%$0 MNov 13, 2026
31Nuveen, LLC1,840New0.01%$0 MNov 10, 2026
32SBI Securities Co., Ltd.1,0250 (0.00%)0.01%$0 MOct 22, 2026
33Osaic Holdings, Inc.985-70 (-6.64%)0.01%$0 MNov 12, 2026
34Group One Trading LLC6860 (0.00%)0.00%$0 MNov 10, 2026
35Royal Bank Of Canada300-2,700 (-90.00%)0.00%$0 MNov 16, 2026
36Jones Financial Companies Lllp250-4,750 (-95.00%)0.00%$0 MNov 13, 2026
37US Bancorp \de\200 (0.00%)0.00%$0 MNov 5, 2026
38BNP Paribas Financial Markets130 (0.00%)0.00%$0 MNov 12, 2026

Mutual funds holding Clene Inc.#

10 funds hold shares worth $3 M (about 3.0% of the company). Since their previous reports 7 added shares and 2 sold, buying $0 M net.
Mutual funds holding Clene Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.231,131$1 M1.6%<0.01%+15%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.99,589$1 M0.69%<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC46,026$0 M0.32%<0.01%+13%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors26,027$0 M0.18%0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC12,397$0 M0.09%<0.01%+25%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC11,366$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC7,401$0 M0.05%<0.01%+53%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.2,986$0 M0.02%<0.01%−59%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,724$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC266$0 M<0.01%<0.01%+14%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Clene Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$217 K
1 purchase, 1 insider
Sold, 12 months
$5.8 M
62 sales, 1 insider
Net, 12 months
-$5.6 M
open market only
Insiders on file
11
since
$583 K-$2.0 M$0Nov 2023: bought $103 K (1 trades), sold $0 (0 trades)Nov 23Apr 2024: bought $0 (0 trades), sold $17 K (5 trades)May 2024: bought $0 (0 trades), sold $5 K (1 trades)MaySep 2024: bought $583 K (3 trades), sold $0 (0 trades)Mar 2025: bought $0 (0 trades), sold $12 K (2 trades)MarMay 2025: bought $0 (0 trades), sold $4 K (4 trades)Jun 2025: bought $0 (0 trades), sold $5 K (2 trades)JunAug 2025: bought $0 (0 trades), sold $18 K (1 trades)Dec 2025: bought $0 (0 trades), sold $2.0 M (20 trades)DecJan 2026: bought $217 K (1 trades), sold $1.1 M (20 trades)Feb 2026: bought $0 (0 trades), sold $38 K (2 trades)FebMar 2026: bought $0 (0 trades), sold $594 K (6 trades)Apr 2026: bought $0 (0 trades), sold $909 K (10 trades)AprMay 2026: bought $0 (0 trades), sold $1.1 M (4 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Clene Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David J. MatlinDirectorGrant or award+434,451$3.280$1.4 M912,275Form 4
filed Alison MoscaDirector, 10% ownerGrant or awardindirect+198,171$3.280$650 K478,671Form 4
filed Robert Dee EtheringtonPresident & CEO, DirectorGrant or award+15,244$3.280$50 K55,393Form 4
filed Chidozie Ugwumba10% ownerSellindirect-73,296$6.200$454 K103,417Form 4
filed Chidozie Ugwumba10% ownerSellindirect-22,177$6.750$150 K176,713Form 4
filed Chidozie Ugwumba10% ownerSellindirect-72,884$6.800$496 K198,890Form 4
filed Chidozie Ugwumba10% ownerSellindirect-5,795$6.010$35 K271,774Form 4
filed Chidozie Ugwumba10% ownerSellindirect-5,736$6.080$35 K277,569Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Clene Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
416,980
3.8% of shares · 5.06 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 1,476 shares at $3.39
  • : 1,439 shares at $3.88
  • : 3,829 shares at $3.92
  • : 4,835 shares at $3.87
  • : 61,929 shares at $3.91

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Clene Inc. scorecard#

Passes 0 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 14, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✗Price to sales below its peers' median203.4×Price to sales 203.4× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-38.1%Free cash flow is -38.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$26 M-$26 M in fiscal 2025 against -$19 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$26 MNet income -$26 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 4
    • ✗Short-term assets cover short-term liabilities0.8×Current ratio 0.83 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-8.6×Operating income -8.6 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-27.30Z-score -27.30 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Clene Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Clene Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue0.20.30.70.50.70.2—
Cost of revenue0.00.10.10.00.3——
Research and development1420273228159.6
General and administrative9.2131417225.26.8
Operating expenses————512016
Total costs and expenses2333414951——
Operating income−23−33−41−48−50−20−16
Interest and finance income0.20.91.40.2———
Interest expense and finance costs2.74.14.63.30.91.00.1
Net interest income———−3.3−0.9——
Other non-operating income (expense)−3.1−6.3−9.018401.30.2
Income before tax−26−39−50−30−10−19−16
Income tax0000−0.40.4—
Net income including minority interests————−9.7−19−16
Net income attributable to shareholders−26−39−50−30−9.7−19−16
Earnings per share, basic-2.65-5.67-9.43r-0.46-0.16-1.10-0.93
Earnings per share, diluted————-0.16-1.10-0.93
Shares, weighted average (basic)9.97.05.2r6562——
Shares, weighted average (diluted)————621817
Balance sheet
Cash and cash equivalents5.212291850r598.8
Short-term investments—06.25.00——
Receivables00.10.10.20.00.0—
Inventory0.00.10.00.00.00.20.0
Other current assets0.1r0.10.60.60.4r3.5r0.7
Current assets9.016392955639.5
Property, plant and equipment6.07.59.3115.24.24.3
Right-of-use (leased) assets3.13.64.24.63.31.01.1
Total assets18275244636815
Accounts payable0.91.21.53.01.91.10.9
Debt due within a year—————5.9—
Current liabilities111025146.0124.3
Lease liabilities (non-current)3.34.14.95.64.41.81.4
Total liabilities36363941506810.0
Retained earnings−308−282−243−193−163−154−70
Shareholders' equity−18−8.9133.2130.3−68
Total liabilities and equity18275244636815
Shares outstanding118.16.4r75626017
Cash-flow statement
Share-based compensation6.48.09.18.5120.80.4
Cash from operating activities−19−21−30−39−35−19−13
Capital expenditure−0.0−0.0−0.3−5.2−1.3−0.4−0.3
Cash from investing activities−0.06.3−1.5−10−1.3−0.4−0.3
Shares issued———110——
Cash from financing activities12−1.5421727705.5
Exchange-rate effect on cash————−0.10.3−0.0
Change in cash−7.0−1710−32−8.950−8.0
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Clene Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$0 M60%
  • Royalty$0 M41%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Clene Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 2 · Material agreement 9 · New debt 1 · Shareholder vote 2 · Results announced 8

Clene Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Directors and officersMaterial agreementShareholder vote8-K
Material agreementResults announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Material agreementNew debtResults announced8-K
Directors and officersShareholder vote8-K
Delisting noticeResults announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Clene Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$7 MPrivate placement after listing$2 to $10 million13equity, optionsSEC
May 2021$9 MPrivate placement after listing$2 to $10 million8equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Clene Inc. compares in Biotechnology

  • Market cap$49 M · higher than 26% of 726
  • Revenue$0 M · higher than 19% of 647
  • Revenue growth-41.2% · higher than 22% of 438
  • Price / sales203.4× · lower than 6% of 339
  • FCF yield-38.1% · higher than 30% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Clene Inc.🇺🇸$49 M——-41.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 14, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Clene Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Clene Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Clene Inc.? Suggest a correction